---
title: '[<sup>18</sup>F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06
  study: protocol for a prospective, multicentre PET/CT trial'
date: '2023-08-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37541751/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230805180723&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'INTRODUCTION: Glioblastoma is the most common aggressive primary central
  nervous system cancer in adults characterised by uniformly poor survival. Despite
  maximal safe resection and postoperative radiotherapy with concurrent and adjuvant
  temozolomide-based chemotherapy, tumours inevitably recur. Imaging with O-(2-[^(18)F]-fluoroethyl)-L-tyrosine
  (FET) positron emission tomography (PET) has the potential to impact adjuvant radiotherapy
  (RT) planning, distinguish between ...'
disable_comments: true
---
INTRODUCTION: Glioblastoma is the most common aggressive primary central nervous system cancer in adults characterised by uniformly poor survival. Despite maximal safe resection and postoperative radiotherapy with concurrent and adjuvant temozolomide-based chemotherapy, tumours inevitably recur. Imaging with O-(2-[^(18)F]-fluoroethyl)-L-tyrosine (FET) positron emission tomography (PET) has the potential to impact adjuvant radiotherapy (RT) planning, distinguish between ...